secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akoya Biosciences, Inc. (—)
CIK:        0001711933
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001104659-25-032006
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akoya signs $30M convertible note deal with Quanterix to fund working capital and repay debt
--------------------------------------------------------------------------------

- Up to $30M in convertible promissory notes to Quanterix; drawn between May 15, 2025 and merger close or July 9, 2025.
- Notes bear SOFR-based interest plus margin; interest paid monthly in cash; subordinated to existing MidCap debt.
- Conversion price tied to exchange ratio under Merger Agreement and Quanterix 10-day VWAP before deal.
- Conversion capped at 19.99% of Akoya common stock unless stockholder approval obtained.
- Registration rights agreement requires Akoya to file resale registration statement by August 13, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711933/000110465925032006/0001104659-25-032006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711933/000110465925032006/tm2511535d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-032006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer